Keeping Patients Safe From Residual Neuromuscular Blockade: The Case for Lower-Dose Sugammadex

Sugammadex (Bridion, Merck) has proven to be superior to acetylcholinesterase inhibitors for the reversal of neuromuscular blockade with a steroidal nondepolarizing neuromuscular blocking agent (NMBA); and, after high-dose rocuronium (1.2 mg/kg), it has been found superior to succinylcholine for return of neuromuscular function after rapid sequence induction. However, even though it has been available since December 2015 in the United States, it is not yet the primary